血液在血管中流动时对血管壁产生的压力称为血压。高血压是指动脉血压(以肘部肱动脉压为代表)高于正常范围。由于各国和地区医疗水平的差异,高血压的确切标准有所不同。我国的标准是:未服用抗高血压药物的情况下,收缩压≥140毫米汞柱(约18.6×10³帕),或舒张压≥90毫米汞柱(约12.0×10³帕),即可诊断为高血压。
临床上将高血压分为两大类。一类是不明病因的高血压,称为“原发性高血压”或“高血压病”。另一类是由其他疾病引起的高血压,如肾炎、脑瘤等疾病导致的血压升高,这种情况下的高血压被称为“继发性高血压”或“症状性高血压”。本文主要介绍前者——原发性高血压,它在中医中属于“眩晕”、“头痛”的范畴。
抗高血压药是用于治疗高血压病的一类药物,也称为降压药。合理使用这些药物不仅能够有效控制血压,还能减轻或消除由高血压引起的主观症状,并降低脑卒中、脑梗塞、心肌梗塞、心力衰竭和肾功能不全等并发症的风险,从而延长患者的寿命。目前,世界各国共研制了约350种抗高血压药,但仅100余种可供临床使用,其中有数十种已被世界卫生组织(WHO)和美国国家高血压教育委员会推荐为常用药物。
根据作用机理的不同,抗高血压药可分为利尿剂、交感神经阻滞剂、血管扩张剂、钙拮抗剂及血管紧张素转化酶抑制剂等五类。近年来,钾通道开放剂和5-羟色胺二型受体拮抗剂也被开发为新型的抗高血压药物,部分新药还在进一步研究中,有的已进入临床试验阶段。
不同类型的抗高血压药物因其作用原理的不同,在血流动力学、药理作用及临床应用等方面存在显著差异。一个理想的抗高血压药物应具备以下特性:易于吸收、降压效果确切且持久;服用后不引起体位性低血压或反射性心动过速;无明显不良反应和毒性作用,不会增加血中肾素活性,无水钠潴留现象,不易产生耐药性,并可与其他药物联合使用。然而,至今尚未发现一种抗高血压药物能够完全满足所有这些要求。
临床医生在选择抗高血压药物时应根据药物特性和患者的具体情况作出合理判断。对于需要合并用药的情况,可根据药物间的异同点,取长补短以减少不良反应并增强疗效。
| 中文名称 | 英文名称 | CAS号 | 化学式 |
|---|---|---|---|
| 1,2,2,6,6-五甲基哌啶 | 1,2,2,6,6-pentamethylpiperidine | 79-55-0 | C10H21N |
| (S)-3-氨基-2,3,4,5-四氢-2-氧-1H-1-苯并氮杂卓-1-乙酸叔丁酯 | (S)-tert-butyl 2-(3-amino-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetate | 109010-60-8 | C16H22N2O3 |
| (S)-(-)-1,2,3,4-四氢异喹啉-3-羧酸 | L-Tic-OH | 74163-81-8 | C10H11NO2 |
| (2R,3R)-2,3-二羟基丁二酸;3-己氧基-4-(1-甲基-3,6-二氢-2H-吡啶-5-基)-1,2,5-噻二唑 | xanomeline tartrate | 152854-19-8 | C4H6O6*C14H23N3OS |
| (2R)-1-[(2R)-3-[2-(环己基甲酰氨基)丙酰硫]-2-甲基丙酰基]吡咯烷-2-甲酸 | Moveltipril | 85856-54-8 | C19H30N2O5S |
| —— | Envacar | 5714-04-5 | C20H28N6O8S |
| —— | alpha-Tocopherol nicotinate | 16676-75-8 | C35H53NO3 |
| —— | 1-[(2R)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]-2-[[(2R)-2-[(2S)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]-2-hydroxyethyl]amino]ethanol | 118457-14-0 | C22H25F2NO4 |
| —— | 3,12,24-Trihydroxy-24,24-diphenyl-cholan | 83116-96-5 | C36H50O3 |
| —— | N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methy]-L-valine | 137863-60-6 | C24H29N5O3 |
| —— | Sodium Nitroprusside | 14402-89-2 | C5H4FeN6Na2O3 |
| —— | oleuropein | 32619-42-4 | C25H32O13 |
| —— | Lisinopril hydrate | 83915-83-7 | C21H33N3O6 |
| —— | (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanolate | 124750-99-8 | C22H22ClN6O- |
| —— | methyl (1R,2S,9R,11S,14R,15S)-2,15-dimethyl-5,5'-dioxospiro[18-oxapentacyclo[8.8.0.01,17.02,7.011,15]octadec-6-ene-14,2'-oxolane]-9-carboxylate | 107724-20-9 | C24H30O6 |
| —— | Metoprolol Succinate | 98418-47-4 | C34H56N2O10 |
| —— | (2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid | 98048-97-6 | C30H46NO7P |
| —— | Zofenopril(1-) | 81938-43-4 | C22H22NO4S2- |
| —— | Methyldopa sesquihydrate | 41372-08-1 | C20H32N2O11 |
| —— | Trimetaphan camsylate | 68-91-7 | C32H40N2O5S2 |
| —— | (4S)-1-[(2S)-3-(benzoylthio)-2-methyl-1-oxopropyl]-4-(phenylthio)-L-proline calcium salt | 81938-43-4 | C44H44CaN2O8S4 |
| —— | 2-Pyrimidinamine, 1,6-dihydro-6-imino-4-(1-piperidinyl)-1-(sulfooxy)- | 83701-22-8 | C9H15N5O4S |
| —— | (2S,4S)-4-cyclohexyl-1-[2-[[(1S)-2-methyl-1-(1-oxopropoxy)propoxy]-(4-phenylbutyl)phosphoryl]-1-oxoethyl]-2-pyrrolidinecarboxylic acid | 98048-97-6 | C30H46NO7P |
| —— | 79-55-0 | C10H21N | |
| —— | (2S,4S)-4-cyclohexyl-1-[2-[[(1R)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid | 98048-97-6 | C30H46NO7P |
| —— | Fosinopril | 98048-97-6 | C30H46NO7P |
| —— | Cozaar | 124750-99-8 | C22H22ClN6O- |
| —— | Carvedilol Phosphate | 610309-89-2 | C48H60N4O17P2 |
| —— | (6R)-2,6-dimethylpiperidine | 504-03-0 | C7H15N |
| —— | methyl (2S,9R,10R,11S,14R,15S,17R)-2,15-dimethyl-5,5'-dioxospiro[18-oxapentacyclo[8.8.0.01,17.02,7.011,15]octadec-6-ene-14,2'-oxolane]-9-carboxylate | 107724-20-9 | C24H30O6 |
| —— | fosinopril sodium | 88889-14-9 | C30H45NO7P*Na |
| —— | methyl (5Z)-4-[2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl]-5-ethylidene-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4H-pyran-3-carboxylate | 32619-42-4 | C25H32O13 |
| —— | (Z)-methyl 4-(2-(3,4-dihydroxyphenethoxy)-2-oxoethyl)-3-ethylidene-2-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-3,4-dihydro-2H-pyran-5-carboxylate | 32619-42-4 | C25H32O13 |
| —— | 4-methyl-pent-3-en-2-one phthalazin-1-yl-hydrazone | 36798-79-5 | C14H16N4 |
| —— | [2S-(2α,3E,4β)]-3-ethylidene-2-(β-D-glucopyranosyloxy)-3,4-dihydro-5-(methoxycarbonyl)-2H-pyran-4-acetic acid 2-(3,4-dihydroxyphenyl)ethyl ester | 32619-42-4 | C25H32O13 |
| —— | (+/-)-exo-mecamylamine hydrochloride | 826-39-1 | C11H21N*ClH |
| —— | hexamethonium bromide | 55-97-0 | 2Br*C12H30N2 |
| —— | losartan potassium | 124750-99-8 | C22H22ClN6O*K |
| —— | oleuropeoside | 32619-42-4 | C25H32O13 |
| —— | Oleuropein | 32619-42-4 | C25H32O13 |
| —— | 11,17-dimethoxy-18-(3,4,5-trimethoxy-benzoyloxy)-yohimbane-16-carboxylic acid methyl ester | 50-55-5 | C33H40N2O9 |
| —— | reserpine | 50-55-5 | C33H40N2O9 |
| —— | 17-methoxy-18-(3,4,5-trimethoxy-benzoyloxy)-yohimbane-16-carboxylic acid methyl ester | 131-01-1 | C32H38N2O8 |
| —— | sodium; 4-cyclohexyl-1-{[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylate | 88889-14-9 | C30H45NO7P*Na |
| —— | rilmenidine hemifumarate | 54187-04-1 | C4H4O4*2C10H16N2O |
| —— | cozaar | 124750-99-8 | C22H22ClN6O*K |
| —— | Amprace | 76095-16-4 | C4H4O4*C20H28N2O5 |
| —— | enalapril maleic acid | 76095-16-4 | C4H4O4*C20H28N2O5 |
| —— | 2-hydroxy-5-<1-hydroxy-2-<(1-methyl-3-phenylpropyl)amino>ethyl>benzamide hydrochloride | 72487-35-5 | C19H24N2O3*ClH |
| —— | terazosin hydrochloride | 63074-08-8 | C19H25N5O4*ClH |